Dr. Roman Zwicky
Dr. Roman Zwicky, CEO of Sobi, is a very experienced marketing director and manager in the medical and pharmaceutical industry. He worked many years for global leading companies like Swedish Orphan Biovitrum AG Switzerland, Biogen Switzerland AG and AstraZeneca.
Dr. Roman Zwicky has a Master title in Biochemistry and later gained PhD in Natural Science. His dissertation is a research work in Biochemistry and Rheumatism. After these chemical and medical educations, Dr. Roman has finished some leadership programs in the area of Marketing and Pharma Business.
Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
- Sobi's research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
- Sobi market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies.
- Sobi have world-class capabilities in protein biochemistry and biologics manufacturing development - validated by leading industry partners.
- Sobi manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.
Sobi's organisation spans 24 countries, delivering therapies to patients in 67 countries across the globe.